Journal of Clinical Neurology · 2016 · 37 citations · 18 references
MedicineNeurologyNeuroscienceNeuroimmunologyNeuropathologyNeuroradiologyDemyelinating DiseasesDemyelinating DisordersMultiple SclerosisNeurologic ImagingAntibody-mediated Neurologic DiseaseCortical Involvement AssessmentFollow-up DurationMedian AgeStructural Mri
BACKGROUND AND PURPOSE: Brain lesions involving the cerebral cortex are rarely described in patients with neuromyelitis optica spectrum disorder (NMOSD), in contrast to multiple sclerosis. We investigated cerebral cortex involvement using conventional brain magnetic resonance imaging (MRI) in anti-aquaporin-4 (AQP4)-antibody-positive NMOSD patients. METHODS: The study enrolled 215 NMOSD patients who were seropositive for the anti-AQP4 antibody from 5 referral hospitals, and retrospectively analyzed their demographic, clinical, and MRI findings. Abnormal cerebral cortex lesions on brain MRI were identified by a neuroradiologist and two neurologists using consensus. RESULTS: Most of the 215 enrolled patients (87%) were female. The median age at onset was 22.5 years (range: 15-36 years) and the mean follow-up duration was 123 months. Brain lesions were found in 143 of 194 patients (74%) in whom MRI was performed during follow-up. Brain lesions involving the cerebral cortex were identified in 6 of these 194 patients (3.1%). Five of the patients were female, and the six patients together had a median age of 29 years (range: 15-36 years) at the time of lesion presentation. Three of them showed leptomeningeal enhancement in the lesions. At presentation of the cortex-involving lesions, five of these patients were not being treated at the time of presentation, while the sixth was being treated with interferon-beta. CONCLUSIONS: Although rare, cortical involvement occurs in NMOSD and is commonly combined with leptomeningeal enhancement. We speculate that this occurs only in patients who are not treated appropriately with immunosuppressant drugs.
18
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett et al. · Neurology · 2015 · 4.5K citations · Full text
Medicine, Neurology, Neuroscience +15
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Vanda A. Lennon, Dean M. Wingerchuk, Thomas J. Kryzer et al. · The Lancet · 2004 · 3.2K citations
Life Sciences, Immunology, Neurology +14
Annabel M. Ruiter, Rosemarijn R. J. Somanje-Bolweg, Erik van Gorsel et al. · PubMed · 2017 · 1.8K citations · Full text
Neuromyelitis Optica and Non–Organ-Specific Autoimmunity
Sean J. Pittock, Vanda A. Lennon, de Sèze et al. · Archives of Neurology · 2008 · 612 citations
Life Sciences, Immunology, Neurology +17
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders
Setty M. Magaña, Marcelo Matiello, Sean J. Pittock et al. · Neurology · 2009 · 197 citations
Medicine, Neurology, Neuroscience +14